Japan targets 'faster than US FDA' medtech approvals, but reimbursement remains a problem
This article was originally published in SRA
Executive Summary
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent ground breaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, senior vice-president of global strategy and analysis at US medtech industry association AdvaMed.